Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.
作者信息
Hapgood Greg, Ben-Neriah Susana, Mottok Anja, Lee Derrick G, Robert Kridel, Villa Diego, Sehn Laurie H, Connors Joseph M, Gascoyne Randy D, Feldman Andrew L, Farinha Pedro, Steidl Christian, Scott David W, Slack Graham W, Savage Kerry J
机构信息
BC Cancer Centre for Lymphoid Cancer and the Department of Medical Oncology, Vancouver, Canada.
Department of Lymphoid Cancer Research, BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada.
出版信息
Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14.
Abstract
摘要
相似文献
1
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.高危DUSP22重排的ALK阴性间变性大细胞淋巴瘤的鉴定
Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14.
2
Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.伴有白血病期的DUSP22重排ALK阴性间变性大细胞淋巴瘤的小细胞模式
Blood. 2022 Jan 20;139(3):465. doi: 10.1182/blood.2021013693.
3
Discovery of G6PD deficiency in a patient with DUSP22-rearranged ALK-negative anaplastic large cell lymphoma in leukemic phase.在处于白血病期的伴有DUSP22重排的ALK阴性间变性大细胞淋巴瘤患者中发现葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症。
Int J Lab Hematol. 2022 Feb;44(1):67-68. doi: 10.1111/ijlh.13583. Epub 2021 May 21.
4
Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.淋巴增强因子（LEF1）过表达与间变性大细胞淋巴瘤 DUSP22 重排的显著关联。
Am J Surg Pathol. 2021 Apr 1;45(4):550-557. doi: 10.1097/PAS.0000000000001614.
5
Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.伴有DUSP22重排的ALK阴性间变性大细胞淋巴瘤的形态学特征
Am J Surg Pathol. 2016 Jan;40(1):36-43. doi: 10.1097/PAS.0000000000000500.
6
[Detection of chromosomal translocations of DUSP22 and TP63 in ALK-negative anaplastic large cell lymphoma by fluorescence in situ hybridization and related clinical relevance].[荧光原位杂交检测ALK阴性间变性大细胞淋巴瘤中DUSP22和TP63的染色体易位及相关临床意义]
Zhonghua Bing Li Xue Za Zhi. 2019 Oct 8;48(10):791-795. doi: 10.3760/cma.j.issn.0529-5807.2019.10.008.
7
Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma.ALK阴性间变性大细胞淋巴瘤亚组鉴定的进展
Biomark Med. 2015;9(8):719-22. doi: 10.2217/BMM.15.37. Epub 2015 Jul 30.
8
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.ALK阴性间变性大细胞淋巴瘤是一种基因异质性疾病，临床结局差异很大。
Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.
9
rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.艾滋病相关ALK阴性间变性大细胞淋巴瘤中的重排
BMJ Case Rep. 2019 Sep 30;12(9):e230641. doi: 10.1136/bcr-2019-230641.
10
DUSP22-rearranged primary cutaneous CD30-positive T-cell lymphoproliferative disorders and adult T-cell leukemia/lymphoma frequently share the LEF1+/TIA1- immunophenotype.DUSP22 重排的原发性皮肤 CD30 阳性 T 细胞淋巴增生性疾病和成人 T 细胞白血病/淋巴瘤常具有 LEF1+/TIA1-免疫表型。
Hum Pathol. 2024 Aug;150:58-66. doi: 10.1016/j.humpath.2024.07.002. Epub 2024 Jul 4.
引用本文的文献
1
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.本妥昔单抗联合化疗一线治疗系统性间变性大细胞淋巴瘤：ECHELON-2研究5年随访的亚组分析
Blood Cancer J. 2025 Aug 1;15(1):129. doi: 10.1038/s41408-025-01329-2.
2
Establishment and characterization of a novel patient-derived TP63-rearranged anaplastic large-cell lymphoma model PTCL-S1.一种新型患者来源的TP63重排间变性大细胞淋巴瘤模型PTCL-S1的建立与鉴定
Hum Cell. 2025 Jul 26;38(5):135. doi: 10.1007/s13577-025-01264-1.
3
Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.间变性大细胞淋巴瘤诊断的分子见解：超越形态学和免疫表型
Int J Mol Sci. 2025 Jun 19;26(12):5871. doi: 10.3390/ijms26125871.
4
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives.结外外周T细胞淋巴瘤：治疗挑战与未来展望
Cancers (Basel). 2025 Mar 28;17(7):1134. doi: 10.3390/cancers17071134.
5
Immunophenotypic Shift From CD8 to CD4 With Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Transformation in Mycosis Fungoides: A Case Report.蕈样肉芽肿中伴有间变性淋巴瘤激酶（ALK）阴性间变性大细胞转化的免疫表型从CD8向CD4转变：一例报告
Cureus. 2025 Mar 1;17(3):e79889. doi: 10.7759/cureus.79889. eCollection 2025 Mar.
6
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.单细胞RNA测序定义了不同的疾病亚型，并揭示了无症状华氏巨球蛋白血症对干扰素的低反应性。
Nat Commun. 2025 Feb 10;16(1):1480. doi: 10.1038/s41467-025-56323-w.
7
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.外周T细胞淋巴瘤的进展：发病机制、基因图谱及新兴治疗靶点
Histopathology. 2025 Jan;86(1):119-133. doi: 10.1111/his.15376.
8
Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors.原发性中枢神经系统间变性大细胞淋巴瘤的临床病理特征：一项多中心研究确定年龄和ALK状态为预后因素。
J Hematop. 2024 Dec;17(4):215-222. doi: 10.1007/s12308-024-00612-8. Epub 2024 Nov 16.
9
New insights into the biology of T-cell lymphomas.T 细胞淋巴瘤生物学的新见解。
Blood. 2024 Oct 31;144(18):1873-1886. doi: 10.1182/blood.2023021787.
10
What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?第五版世界卫生组织成熟 B 和 T/NK 细胞肿瘤和间质肿瘤分类有哪些新内容？
J Hematop. 2024 Jun;17(2):71-89. doi: 10.1007/s12308-024-00585-8. Epub 2024 Apr 29.
本文引用的文献
1
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements.分子谱分析揭示了具有重排的间变大细胞淋巴瘤中的免疫原性线索。
Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.
2
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.NCCN 指南解读：T 细胞淋巴瘤，第 2.2018 版。
J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007.
3
and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.重排可预测ALK阴性间变性大细胞淋巴瘤的预后：一项丹麦队列研究。
Blood. 2017 Jul 27;130(4):554-557. doi: 10.1182/blood-2016-12-755496. Epub 2017 May 18.
4
The biology and management of systemic anaplastic large cell lymphoma.系统性间变性大细胞淋巴瘤的生物学特性与治疗策略。
Blood. 2015 Jul 2;126(1):17-25. doi: 10.1182/blood-2014-10-567461. Epub 2015 Apr 13.
5
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.ALK阴性间变性大细胞淋巴瘤是一种基因异质性疾病，临床结局差异很大。
Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.
6
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.全基因组分析揭示了外周 T 细胞淋巴瘤中 TP63 和其他 p53 相关基因的反复出现的结构异常。
Blood. 2012 Sep 13;120(11):2280-9. doi: 10.1182/blood-2012-03-419937. Epub 2012 Aug 1.
7
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.TBL1XR1/TP63：B 细胞非霍奇金淋巴瘤中的一种新型重现性基因融合。
Blood. 2012 May 24;119(21):4949-52. doi: 10.1182/blood-2012-02-414441. Epub 2012 Apr 11.
8
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.通过大规模平行基因组测序发现 ALK 阴性间变性大细胞淋巴瘤中反复出现的 t(6;7)(p25.3;q32.3)易位。
Blood. 2011 Jan 20;117(3):915-9. doi: 10.1182/blood-2010-08-303305. Epub 2010 Oct 28.
Zotero 插件